← Back to Search

Palliative Care

Palliative Care for Multiple Myeloma

N/A
Waitlist Available
Led By Renato Samala, MD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have an ECOG performance status of 0, 1, 2 or 3
Be older than 18 years old
Must not have
Need immediate referral to PC for hospice transition
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, 6 months, 9 months and 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether getting palliative care early on (alongside usual cancer care) can help people with newly diagnosed multiple myeloma.

Who is the study for?
This trial is for English-speaking individuals recently diagnosed with symptomatic Multiple Myeloma, within eight weeks. They should be able to perform daily activities with varying degrees of assistance (ECOG status 0-3) and must be receiving care at a Cleveland Clinic facility. Those who have already seen a Palliative Care provider or require immediate hospice care cannot participate.
What is being tested?
The study is examining the impact of early Palliative Care on quality of life for new Multiple Myeloma patients. It involves assessing symptom relief and well-being using specific questionnaires like FACT-MM and HADS during the treatment process.
What are the potential side effects?
Since this trial focuses on Palliative Care rather than direct medical treatments, side effects are not typical as in drug trials. However, emotional discomfort or distress from discussing symptoms or personal matters during assessments may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can care for myself but may not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need to be referred to palliative care for end-of-life care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, 6 months, 9 months and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months, 6 months, 9 months and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in QOL relative to baseline as measured by FACT-MM scores
Health services utilization as measured by number of ER visits, hospital admissions or ICU admissions
Number of PC visits made in the first 12 months after diagnosis
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Early Palliative Care IntegrationExperimental Treatment3 Interventions
12 months of PC with concurrent standard treatment for MM, QOL assessments

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
469 Previous Clinical Trials
33,450 Total Patients Enrolled
27 Trials studying Multiple Myeloma
1,705 Patients Enrolled for Multiple Myeloma
Renato Samala, MDPrincipal InvestigatorThe Cleveland Clinic

Media Library

Palliative Care (Palliative Care) Clinical Trial Eligibility Overview. Trial Name: NCT04248244 — N/A
Multiple Myeloma Research Study Groups: Early Palliative Care Integration
Multiple Myeloma Clinical Trial 2023: Palliative Care Highlights & Side Effects. Trial Name: NCT04248244 — N/A
Palliative Care (Palliative Care) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04248244 — N/A
~3 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top